Le Lézard
Classified in: Health, Science and technology
Subjects: Stock Sale/Buyback, Share Issue

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on April 1, 2022 as inducement material to such employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $15.00 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista's oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information, please visit www.kalvista.com.


These press releases may also interest you

at 15:01
In a first-of-its-kind trial, a federal judge has ordered a $650.6 million judgment sought by two Ohio counties against retail giants CVS Health Corp., Walgreens Boots Alliance Inc and Walmart Inc. for their roles in failing to control the spread of...

at 15:00
Élisabeth Brière, Parliamentary Secretary to the Minister of Mental Health and Addictions and Associate Minister of Health, on behalf of the Honourable Carolyn Bennett, Minister of Mental Health and Addictions and Associate Minister of Health, will...

at 15:00
This summer, the Golisano Institute for Developmental Disability Nursing at St. John Fisher University's Wegmans School of Nursing earned accreditation for nursing continuing professional development from the American Nurses Credentialing Center...

at 15:00
Smile Brands, one of the nation's leading dental support organizations (DSO), is pleased to announce its new affiliate partnership with Meadow Place Dental in East Longmeadow, MA. Dr. Lawrence Life and Dr. Jennifer Walsh, along with associate Dr....

at 14:49
The Prime Minister, Justin Trudeau, today welcomed the Twenty-Ninth Annual Report on the Public Service of Canada, which was presented to him by the Clerk of the Privy Council and Secretary to the Cabinet and Head of the Federal Public Service,...

at 14:47
As the nationwide nursing shortage persists, the Health Foundation of South Florida, the region's largest philanthropic organization focused on achieving health equity in underserved communities, announced a $1 million investment to fund expanded...



News published on 4 april 2022 at 16:20 and distributed by: